Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

H, Chehrehgosha; MR, Sohrabi; F, Ismail-Beigi; M, Malek; Babaei M, Reza; F, Zamani; H, Ajdarkosh; M, Khoonsari; AE, Fallah; ME, Khamseh

doi:10.1007/s13300-021-01011-3

Public

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Shared by NobleBlocks on Feb 14, 2021 • 12:00 AM UTC

Authors:

Chehrehgosha H

Sohrabi MR

Ismail-Beigi F

Abstract

<h4>Introduction</h4>To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM).<h4>Methods</h4>In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD an...

Subject

Liver fibrosis

Body composition

pioglitazone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!